Assembling intelligence…
PRECLINICAL EFFICACY & INTERMEDIATE ENDPOINT BIOMARKERS IDIQ CONTRACT IN SUPPORT OF THE PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM
| Company | Orders | Obligated | Latest order end |
|---|---|---|---|
| THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 2 | $1.2M | 2027-03-24 |
| 75N91025F00001 THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER · National Institutes of Health | $692K | 2027-03-24 |
| 75N91024F00002 THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER · National Institutes of Health | $552K | 2026-12-19 |